RESTOREGI Study Evaluates Regenerative Therapy for Benign GI Fistulas
The RESTOREGI study aims to identify factors influencing healing in benign gastrointestinal fistulas treated with tSVF-EM therapy.
Asset / Drug
Drug and asset intelligence for RESTOREGI with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Regenerative Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.